Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | PLB1004 |
| Synonyms | |
| Therapy Description |
PLB1004 is an EGFR inhibitor with activity against L858R, T790M, exon 19 deletions, and exon 20 insertion mutations, which potentially decreases tumor growth (Cancer Res (2023) 83 (8_Supplement): CT102). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| PLB1004 | PLB 1004|PLB-1004 | EGFR Exon 20 Insertion Inhibitor 15 EGFR Inhibitor (Pan) 63 | PLB1004 is an EGFR inhibitor with activity against L858R, T790M, exon 19 deletions, and exon 20 insertion mutations, which potentially decreases tumor growth (Cancer Res (2023) 83 (8_Supplement): CT102). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06046495 | Phase I | PLB1004 | A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer | Recruiting | USA | 0 |